Kantar Health Blog

  • Stephanie Hawthorne
    The “Profile” of Xalkori at ESMO 2012 has cemented the idea of pursuing personalized medicine. Together with the past data on the EGFR inhibitors in patients with EGFR activating mutations, no physician treating a NSCLC patient will reflexively reach for chemotherapy without thinking first of the unique molecular characteristics associated with each individual patient’s tumor.
    Continue Reading > | Go comment! | Share
  • Go for the Gold!

    by Stephanie Hawthorne | Aug 1, 2012
    Stephanie Hawthorne
    So what analogies can be drawn between the Olympics and oncology? Mediocre performance won’t earn you a gold medal. A personal best is great for your growth and development, but you still have to beat all other competitors to win the gold. Several new entrants have blockbuster potential, which is arguably the equivalent of a gold medal for pharma.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    In ovarian cancer, Avastin plus chemotherapy achieved significant improvement in primary endpoint of median progression-free survival (mPFS= 6.7 months in Avastin plus chemotherapy versus 3.4 months in control arm; HR 0.48, p<0.001). ASCO 2012
    Continue Reading > | Go comment! | Share
  • Zytiga Takes the Lead in Asymptomatic mCRPC

    by Stephanie Hawthorne | Jun 2, 2012
    Stephanie Hawthorne
    Zytiga quickly established itself as standard of care in second-line CRPC following its approval in 2011, but its favorable safety profile and high level of efficacy have prompted a wide desire to move the drug into earlier lines of therapy, specifically prior to chemotherapy. ASCO 2012
    Continue Reading > | Go comment! | Share
Page